|Bid||298.00 x 1300|
|Ask||306.00 x 900|
|Day's Range||297.57 - 306.00|
|52 Week Range||196.78 - 404.20|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||69.97|
|Earnings Date||Jan 27, 2021 - Feb 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||296.47|
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.
Liquid biopsy technology offers promise of the medical Holy Grail, early detection of multiple cancers. Illumina, Exact Sciences deals heating up a game-changing field in cancer treatment.
. Illumina, Inc. (NASDAQ: ILMN) is further extending the reach of the NextSeq™ 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1 billion reads in a single sequencing run, almost three times more than previously available on Illumina’s mid-throughput NextSeq sequencing portfolio, expanding the range of applications that run on the system.